• Alias: OMP-18R5
    • Fully human IgG2 monoclonal antibody targeting frizzled receptor of Wnt pathway
    • Selectively reduces frequency of cancer stem cells in patient-derived xenograft models
    • Currently under investigation in phase 1 clinical trials for untreated NSCLC and stage IV pancreatic cancer, and metastatic breast cancer
    • Recommended dose: 10 mg/kg IV every 3 weeks
    • Half-life: 1.5 to 3.8 days
    • Common side effects: Fatigue, nausea/vomiting, anorexia, hypercalcemia, constipation
    (Papadopoulos et al., 2013)
    Other topics in Targeted and Immunotherapy Agents